Literature DB >> 21818113

Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.

M Deckert1, A Engert, W Brück, A J M Ferreri, J Finke, G Illerhaus, W Klapper, A Korfel, R Küppers, M Maarouf, M Montesinos-Rongen, W Paulus, U Schlegel, H Lassmann, O D Wiestler, R Siebert, L M DeAngelis.   

Abstract

Recent studies addressing the molecular characteristics of PCNSL, which is defined as malignant B-cell lymphoma with morphological features of DLBCL, have significantly improved our understanding of the pathogenesis of this lymphoma entity, which is associated with an inferior prognosis as compared with DLBCL outside the CNS. This unfavorable prognosis stimulated intense efforts to improve therapy and induced recent series of clinical studies, which addressed the role of radiotherapy and various chemotherapeutic regimens. This review combines the discussion of diagnosis, differential diagnosis and recent progress in studies addressing the molecular pathogenesis as well as therapeutic options in PCNSL.

Entities:  

Mesh：

Year:  2011        PMID： 21818113     DOI： 10.1038/leu.2011.169

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  44 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.

Authors:  Alexander Baraniskin; Jan Kuhnhenn; Uwe Schlegel; Wolf Schmiegel; Stephan Hahn; Roland Schroers
Journal:  J Neurooncol       Date:  2012-06-23       Impact factor: 4.130

3.  Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Ariz Akhter; Noraidah Masir; Ghaleb Elyamany; Kean-Chang Phang; Etienne Mahe; Ali Matar Al-Zahrani; Meer-Taher Shabani-Rad; Douglas Allan Stewart; Adnan Mansoor
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

Review 4.  Primary central nervous system lymphoma: essential points in diagnosis and management.

Authors:  Semra Paydas
Journal:  Med Oncol       Date:  2017-03-17       Impact factor: 3.064

5.  Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma.

Authors:  F E Valles; C L Perez-Valles; S Regalado; R F Barajas; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2012-08-30       Impact factor: 3.825

Review 6.  Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes.

Authors:  Kieron Dunleavy; Mark Roschewski; Wyndham H Wilson
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

7.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

Authors:  I Vater; M Montesinos-Rongen; M Schlesner; A Haake; F Purschke; R Sprute; N Mettenmeyer; I Nazzal; I Nagel; J Gutwein; J Richter; I Buchhalter; R B Russell; O D Wiestler; R Eils; M Deckert; R Siebert
Journal:  Leukemia       Date:  2014-09-05       Impact factor: 11.528

8.  [Primary vitreoretinal lymphoma].

Authors:  D Jaehne; S E Coupland
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

9.  Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center.

Authors:  Samir Dalia; Peter Forsyth; Julio Chavez; Samantha Price; Bijal Shah; Celeste Bello; Lubomir Sokol; Edward Pan; Eduardo Sotomayor; Ji-Hyun Lee; Kate Fisher; Michael Jaglal
Journal:  Int J Hematol       Date:  2014-03-01       Impact factor: 2.490

Review 10.  Diagnosis and treatment of primary CNS lymphoma.

Authors:  Agnieszka Korfel; Uwe Schlegel
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.